Arcus Biosciences (RCUS) FY2020 results: revenue $78 million, up 420.0% on the year
Arcus Biosciences, Inc. (RCUS) reported revenue of $78 million for fiscal 2020, the year ended 31 December 2020, up 420.0% on the year before. Net income was -$123 million, and diluted earnings per share $-2.24. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2021.
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
| $ million | FY2020 | FY2019 | FY2018 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Revenue | 78.0 | 15.0 | 8.4 | +420.0% | |
| Research and development | 159 | 78.5 | 49.6 | +102.6% | |
| Operating income | -124 | -88.7 | -54.9 | ||
| Operating margin | -159.3% | -591.4% | -656.8% | ||
| Pre-tax income | -123 | -84.7 | n/a | ||
| Net income | -123 | -84.7 | -49.6 | ||
| Net margin | -157.5% | -564.7% | -593.7% | ||
| Diluted EPS | -$2.24 | -$1.93 | -$1.43 |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | FY2020 | FY2019 | FY2018 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Operating cash flow | 111 | -73.5 | -43.0 | ||
| Capital expenditure | 3.0 | 1.9 | 3.7 | +55.8% | |
| Free cash flow | 108 | -75.4 | -46.7 | ||
| Free cash flow margin | 138.7% | -502.6% | -559.5% | ||
| Cash from investing | -434 | 59.2 | -113 | ||
| Cash from financing | 439 | 1.1 | 129 | +38,962.8% | |
| Depreciation and amortisation | 3.0 | 3.6 | 3.7 | -16.2% | |
| Share-based compensation | 22.0 | 9.0 | 3.9 | +145.0% | |
| Buybacks | n/a | 0.1 | 0.0 | ||
| Diluted shares, weighted | 55m | 44m | 36m | +25.0% | |
| Shares outstanding at period end | 65m | 46m | 45m | +41.8% |
Balance sheet
| $ million | FY2020 | FY2019 | FY2018 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Shareholders' equity | 502 | 164 | 235 | +206.6% | |
| Redeemable equity | n/a | n/a | 0.0 | ||
| Debt | 0.0 | 0.0 | 0.0 | ||
| Operating lease liabilities | 15.2 | n/a | n/a | ||
| Other liabilities | 255 | 39.3 | 40.0 | +548.7% | |
| Total liabilities and equity | 772 | 203 | 275 | +280.2% | |
| Fixed assets | 10.8 | 9.3 | 11.1 | +15.8% | |
| Investments | 562 | 130 | 189 | +331.0% | |
| Cash and equivalents | 173 | 57.9 | 71.1 | +199.3% | |
| Other assets | 26.4 | 5.5 | 4.1 | +379.1% | |
| Total assets | 772 | 203 | 275 | +280.2% |
10-K for the year ended 31 December 2020, filed 25 February 2021: the filing.